Risk Indicators of Sarcoidosis Evolution-Unified Protocol
ConditionSarcoidosis, Pulmonary
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorUniversity of California, San Francisco
About this trial
The purpose of this study is to develop prediction models that can prognosticate patients with sarcoidosis using clinical data and blood markers that can be obtained during a clinic visit.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults with a diagnosis of sarcoidosis over the age of 18
Case definition: we will follow the 1999 statement on sarcoidosis published by the American Thoracic Society for diagnosis which includes tissue biopsy confirmation and exclusion of alternative diagnoses including beryllium sensitization/chronic beryllium disease, mycobacterial, viral, and/or fungal infection
Disqualifiers
Inability to tolerate study procedures as determined by the investigator
Pregnant or breastfeeding
Concurrent medical diagnoses that would influence the expression of biomarkers will be considered an exclusion criterion. This includes diseases such as common variable immunodeficiency, HIV infection, or autoimmune diseases
Concurrent interstitial lung diseases such as hypersensitivity pneumonitis or idiopathic pulmonary fibrosis
Trial population
adults who meet criteria for the diagnosis of pulmonary sarcoidosis
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Mean Change in Forced Vital Capacity in Liters
Forced vital capacity (FVC) is the total amount of air in liters exhaled during a forced maneuver.
Time frame
Baseline and 24 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of California, San Francisco
Lead sponsor
Vanderbilt University Medical Center
Collaborator
University of Texas, Southwestern Medical Center at Dallas
Collaborator
Wayne State University
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov